Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Endocrinology 2, 258–259 (1 May 2006) | doi:10.1038/ncpendmet0171
Do markers of bone turnover predict clinical outcome in patients with bone metastases?
Abstract
Coleman RE et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935 Synopsis Background Patients with advanced solid tumors frequently experience bone metastases, which increase rates of bone turnover.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
